These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1776388)

  • 1. Selegiline and cognitive function in Parkinson's disease.
    Hietanen MH
    Acta Neurol Scand; 1991 Nov; 84(5):407-10. PubMed ID: 1776388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline hydrochloride and cognition.
    Lees AJ
    Acta Neurol Scand Suppl; 1991; 136():91-4. PubMed ID: 1801544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of selegiline on cognitive functions in Parkinson's disease.
    Dixit SN; Behari M; Ahuja GK
    J Assoc Physicians India; 1999 Aug; 47(8):784-6. PubMed ID: 10778622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.
    Dalrymple-Alford JC; Jamieson CF; Donaldson IM
    Clin Neuropharmacol; 1995 Aug; 18(4):348-59. PubMed ID: 8665548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I
    Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Vuorinen JA; Heinonen EH
    Acta Neurol Scand Suppl; 1991; 136():70-2. PubMed ID: 1801540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lisuride plus selegiline in the treatment of early Parkinson's disease.
    Nappi G; Martignoni E; Horowski R; Pacchetti C; Rainer E; Bruggi P; Runge I
    Acta Neurol Scand; 1991 Jun; 83(6):407-10. PubMed ID: 1909485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment.
    Imamura K; Okayasu N; Nagatsu T
    Acta Neurol Scand; 2011 Jul; 124(1):28-39. PubMed ID: 20880269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
    Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
    Takahashi M; Yuasa R; Imai T; Tachibana H; Yorifuji S; Nakamura Y; Ogawa N
    Intern Med; 1994 Sep; 33(9):517-24. PubMed ID: 8000101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
    Myllylä VV; Sotaniemi KA; Hakulinen P; Mäki-Ikola O; Heinonen EH
    Acta Neurol Scand; 1997 Apr; 95(4):211-8. PubMed ID: 9150811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
    Allain H; Pollak P; Neukirch HC
    Mov Disord; 1993; 8 Suppl 1():S36-40. PubMed ID: 8302306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S; Heinonen EH; Hägglund J; Kaugesaar T; Kontants H; Mäki-Ikola O; Palm R; Turunen J
    Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.